Danaher Corp. closed 33.68% short of its 52-week high of $281.70, which the company achieved on August 1st.

Buying $100 In DHR: If an investor had bought $100 of DHR stock 10 years ago, it would be worth $326.41 today based on a ...

We recently published a list of 10 Best Medical Stocks to Buy According to Billionaires. In this article, we are going to ...

Andvari Associates, an investment management firm, released its first-quarter 2025 investor letter. A copy of the letter can ...

Baird analyst Catherine Ramsey Schulte lowered the firm’s price target on Danaher (DHR) to $231 from $258 and keeps an Outperform rating on the ...

Danaher Corp. closed 33.00% below its 52-week high of $281.70, which the company achieved on August 1st.

Whales with a lot of money to spend have taken a noticeably bullish stance on Danaher. Looking at options history for Danaher ...

DHR is poised to gain from strength in the clinical diagnostics business, the Abcam buyout and shareholder-friendly policies.

BofA lowered the firm’s price target on Danaher (DHR) to $230 from $265 and keeps a Buy rating on the shares. Sentiment for Life Sciences and ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

Danaher Corporation incorporates science and technology and has a market cap of $150B. The company has mixed financials, with its gross profit margin being its strongest and most consistent.

In this article, we are going to take a look at where Danaher Corporation (NYSE:DHR) stands against other best medical stocks to buy according to billionaires. Some experts view medical ...